^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    OXB302

    i
    Other names: OXB302, OXB-302, OXB 302
    Company:
    Oxford Biomedica
    Drug class:
    5T4-targeted CAR-T immunotherapy
    over2years
    OXB-302: 5T4-Targeting CAR-T Cells Are Cytotoxic Against Low-Expressing Cells and Successfully Eliminate Leukaemic Stem Cells In Vitro (ASGCT 2022)
    Together, these data evidence the fact that 5T4-targeted CAR-T cells show specificity and efficient of cell killing. This suggests that OXB-302 could successfully kill 5T4-expressing leukaemic blasts from AML patients and further eliminate 5T4-expressing leukaemic stems cells, which would help to prevent relapse.
    Preclinical • CAR T-Cell Therapy • IO biomarker
    |
    CD38 (CD38 Molecule) • TPBG (Trophoblast Glycoprotein) • CD34 (CD34 molecule)
    |
    TPBG expression
    |
    OXB302